CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Bupivacaine liposome +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03502018
NCT03502018Phase 4Completed
CompareCT.gov

Evaluation of the Efficacy of Exparel Delivered Into the Hip Capsule During Hemiarthroplasty

Maimonides Medical Center·interventional·Posted Apr 18, 2018·Updated Nov 18, 2023

In Brief

A Phase 4 clinical trial evaluating Bupivacaine liposome and Saline for Intracapsular Fracture of Femur and 2 related conditions. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This study will examine the efficacy of Liposomal Bupivacaine (Exparel) in hip fracture patients undergoing hip hemiarthroplasty for femoral neck fractures through a posterior approach. Post-operative measures will be assessing pain, overall opiate use, delirium, time-to-ambulation and discharge status.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntracapsular Fracture of Femur, Femoral Neck Fractures, Hip Hemiarthroplasty
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedApr 18, 2018
Enrollment StartMar 1, 2018
Primary CompletionAug 31, 2023
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 8.2 years ago

Interventions

Bupivacaine liposomedrug

A long-acting liposomal bupivacaine

Salinedrug

Saline injection used as control